

Contents

| | |
|---|------|
| Contributors | vii |
| Acknowledgments | xi |
| Introduction | xiii |
| 1. The Wide Spectrum of Pulmonary Vascular Diseases: “The Sick Lung Circulation” | I |
| Norbert F. Voelkel | |
| 2. Mechanisms of Lung Vascular Remodeling | 11 |
| Norbert F. Voelkel | |
| 3. Ion Channels and Transporters in Pulmonary Arterial Hypertension | 19 |
| Thenappan Thenappan, Lin Piao, Jalees Rehman, and Stephen L. Archer | |
| 4. Reconciling Matrix Remodeling and Vasoconstriction in Pulmonary Hypertension | 51 |
| Peter Lloyd Jones | |
| 5. The Immune Response in Pulmonary Hypertension | 67 |
| Yon K. Sung and Mark R. Nicolls | |
| 6. The Pathobiology of the Complex Vascular Lesions in Severe Pulmonary Hypertension—Angiogenesis and Cancer | 87 |
| Norbert F. Voelkel and Carlyne D. Cool | |
| 7. Pulmonary Venocclusive Disease | 105 |
| David Montani, Dermot S. O’Callaghan, and Marc Humbert | |
| 8. Left Heart–Related Pulmonary Venous Hypertension | 119 |
| Julio Sandoval, Arturo Carrillo, Felipe Massó, Virgilia Soto, Rodolfo Barragán, Tomás Pulido, Valentin Herrera, Efrén Santos, and Norbert Voelkel | |
| 9. Pulmonary Hypertension and Interstitial Lung Disease | 141 |
| Laszlo Farkas and Martin R.J. Kolb | |
| 10. Animal Models of Pulmonary Hypertension | 161 |
| Norbert F. Voelkel | |
| 11. Right Heart Failure in Pulmonary Hypertension | 177 |
| Herman J. Bogaard, Ramesh Natarajan, Jose Gomez-Arroyo, Antonio Abbate, and Norbert F. Voelkel | |
| 12. Genetics of Severe Pulmonary Hypertension | 197 |
| Rajiv D. Machado, Richard C. Trembath, and Nicholas W. Morrell | |
| 13. Pulmonary Hypertension in Children | 211 |
| Christian Apitz and Dietmar Schranz | |

| | |
|---|------------|
| 14. Endocrine Aspects of Pulmonary Hypertension | 239 |
| Lori B. Sweeney and Laveena Chhatwani | |
| 15. The Role of Exercise in the Prognosis, Diagnosis and Management of Pulmonary Arterial Hypertension | 251 |
| Daniel C. Grinnan, Ross Arena, and Herman J. Bogaard | |
| 16. Treatment Strategies for Severe PAH: The Present and Future | 269 |
| Dermot S. O'Callaghan, Marc Humbert, and Gérald Simonneau | |
| 17. Inhaled Drugs for the Treatment of Pulmonary Hypertension: Challenges and Benefits | 281 |
| Peter R. Byron and Masahiro Sakagami | |
| 18. Biomarkers, Registries, and Outcomes | 301 |
| R. Paul Fairman | |
| 19. On the Pathobiology and Treatment of Cancer and Pulmonary Arterial Hypertension | 317 |
| Roland Mertelsmann and Ralph Wäsch | |
| Epilogue | 341 |
| Index | 345 |